Description
MM-141 is an investigational drug being studied by Merrimack Pharmaceuticals. It is currently in Phase 1 clinical trials, often in combination with other drugs like MM-151 and MM-121. These early-stage trials are designed to determine the safest dose and how patients respond to the treatment. The trials mentioned (like NCT02538627) are exploring MM-141 in patients with advanced cancers, including colorectal cancer, specifically those that are 'heregulin-positive'. This means the drug is being tested in a specific subset of patients whose tumors might have certain characteristics. The goal of these Phase 1 trials is to find the best way to give the drug and to see if it has any effect on the cancer. It is not yet approved for use in colorectal cancer or any other cancer.
Mechanism of Action
MM-141 is being studied in clinical trials. The specific way it works (its mechanism of action) is being investigated. It is being tested in combination with other drugs (MM-151, MM-121, trametinib) in patients with certain types of advanced cancers, including colorectal cancer. The trials focus on patients whose tumors are 'heregulin-positive', suggesting the drug might target pathways related to heregulin signaling, which plays a role in cell growth and survival.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.